Last reviewed · How we verify
ABT-348 and docetaxel
Docetaxel is a microtubule inhibitor that works by stabilizing microtubules and preventing cell division.
Docetaxel is a microtubule inhibitor that works by stabilizing microtubules and preventing cell division. Used for Non-small cell lung cancer, Breast cancer, Prostate cancer.
At a glance
| Generic name | ABT-348 and docetaxel |
|---|---|
| Sponsor | AbbVie (prior sponsor, Abbott) |
| Drug class | Taxane |
| Target | Microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Docetaxel is a chemotherapeutic agent that interferes with the normal function of microtubules during cell division, leading to cell cycle arrest and apoptosis.
Approved indications
- Non-small cell lung cancer
- Breast cancer
- Prostate cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-348 and docetaxel CI brief — competitive landscape report
- ABT-348 and docetaxel updates RSS · CI watch RSS
- AbbVie (prior sponsor, Abbott) portfolio CI